Evaluation of role of remdesivir in covid-19 patients outcome: A retrospective analysis

Coronavirus disease 2019 (COVID-19) is a contagious caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir, broad spectrum antiviral agent, currently the only drug that approved Food and Drug Administration for treatment of COVID-19. It recommended use in hospitalized patients who require supplemental oxygen. There are insufficient data either or against to recommend routine Remdesivir high risk doesn’t To evaluate efficacy covid positive patients. A retrospective analysis 300 was done, out which 150 belong Group 1 2. 1-Elderly with comorbidities oxygen 2- Patients requiring supplementation (SpO2 88% 94% on room air). were discharged earlier than Elective has definitive role prevention progression especially susceptible individuals.